【摘要】 背景与目的复发的小细胞肺癌化疗效果不佳,目前缺乏有效的化疗方案。本研究旨在探讨拓普替康与顺铂联合治疗复治的小细胞肺癌的近期疗效与毒性反应。方法全组共28例复发的小细胞肺癌患者。拓普替康1.2mg/m2,第1~4天,顺铂25mg/m2,第5~7天,每3周为1周期,患者至少治疗2周期。结果共取得完全缓解1例,部分缓解10例,总有效率为39.3%,其中难治性复发组与敏感性复发组有效率分别为37.5%(3/8)和40.0%(8/20)。中位疾病进展时间为4.2个月。主要毒性反应是血液学毒性,Ⅲ、Ⅳ度中性粒细胞减少为42.9%(12/28)。结论拓普替康与顺铂作为二线方案治疗复发的小细胞肺癌,疗效肯定。主要毒性反应为血液毒性,及时应用集落刺激因子,可耐受治疗。更多还原

【Abstract】 Background and objective There is no effective regimen for recurrent small cell lung cancer patients now. The aim of this study is to assess the activity and toxicity of topotecan combined with cisplatin in the treatment of recurrent small cell lung cancer patients. Methods Twenty-eight patients with progressive disease after one first-line regimen enrolled in the study from May 2002 to October 2004. Topotecan was given at the dose of 1.2mg/m2 from 1st to 4th days and cisplatin was administered at the dose of 25mg/m2 from 5th to 7th days in a cycle of 3 weeks. The patients could be evaluated at least after 2 cycles. Results One patient got complete response and ten patients got partial response in this group. The overall response rate was 39.3% , and the response rate of refractory group and sensitive group was 37.5% (3/8) and 40.0% (8/20) respectively. The median time to progression was 4.2 months. The main toxicity was hematological toxicity. Grade Ⅲ+Ⅳ neutropenia occurred in 42.9% (12/28) of the patients. Conclusion The regimen of topotecan and cisplatin shows better activity in retreated small cell lung cancer patients. The main toxicity is hematological toxicity and can be tolerated.更多还原